Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease

Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease

Background: Up to 30% of patients with pediatric inflammatory bowel disease (IBD) do not respond to anti-Tumor Necrosis Factor (anti-TNF) therapy. The aim of this study was to identify pharmacogenomic markers that predict early response to anti-TNF drugs in pediatric patients with IBD. Methods: An o...

Full description

Bibliographic Details
Main Authors: Sara Salvador-Martín, Bartosz Kaczmarczyk, Rebeca Álvarez, Víctor Manuel Navas-López, Carmen Gallego-Fernández, Ana Moreno-Álvarez, Alfonso Solar-Boga, Cesar Sánchez, Mar Tolin, Marta Velasco, Rosana Muñoz-Codoceo, Alejandro Rodriguez-Martinez, Concepción A. Vayo, Ferrán Bossacoma, Gemma Pujol-Muncunill, María J. Fobelo, Antonio Millán-Jiménez, Lorena Magallares, Eva Martínez-Ojinaga, Inés Loverdos, Francisco J. Eizaguirre, José A. Blanca-García, Susana Clemente, Ruth García-Romero, Vicente Merino-Bohórquez, Rafael González de Caldas, Enrique Vázquez, Ana Dopazo, María Sanjurjo-Sáez, Luis A. López-Fernández
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Pharmaceutics
Subjects:
biomarker
gene expression
infliximab
adalimumab
ulcerative colitis
Crohn disease
Online Access:https://www.mdpi.com/1999-4923/13/1/77

Internet

https://www.mdpi.com/1999-4923/13/1/77

Similar Items